[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) breast cancers. Yet, response in these populations re...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah B. Gitto, Austin R. Pantel, Kara N. Maxwell, Daniel A. Pryma, Michael D. Farwell, Fang Liu, Quy Cao, Sophia R. O’Brien, Amy S. Clark, Payal D. Shah, Elizabeth S. McDonald
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-025-00791-0
Tags: Add Tag
No Tags, Be the first to tag this record!